Anti-STEAP1 CAR T-cells
PreclinicalCell therapy
Anti-STEAP1 CAR T-cells is one of 7 biologic programs targeting Metastatic Castration-Resistant Prostate Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Metastatic Castration-Resistant Prostate Carcinoma
#DrugCompanyPhaseTrials
1Lutetium Lu-177 PNT2002
JJonsson Comprehensive Cancer Center
Phase 3
Xtandi
AstellasPreclinical
Fludara
SanofiPreclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Bavencio
EMD SeronoPreclinical
Peposertib
Merck & Co.Preclinical
Anti-STEAP1 CAR T-cells
FFred Hutchinson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-STEAP1 CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- FFred Hutchinson Cancer Center